000862734 001__ 862734
000862734 005__ 20220930130211.0
000862734 0247_ $$2doi$$a10.1093/neuonc/noz083
000862734 0247_ $$2ISSN$$a1522-8517
000862734 0247_ $$2ISSN$$a1523-5866
000862734 0247_ $$2altmetric$$aaltmetric:60296510
000862734 0247_ $$2pmid$$apmid:31077276
000862734 0247_ $$2WOS$$aWOS:000493086800015
000862734 037__ $$aFZJ-2019-02976
000862734 082__ $$a610
000862734 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b0$$eCorresponding author$$ufzj
000862734 245__ $$aPhotopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET - Clinical relevance in glioma patients
000862734 260__ $$aOxford$$bOxford Univ. Press$$c2019
000862734 3367_ $$2DRIVER$$aarticle
000862734 3367_ $$2DataCite$$aOutput Types/Journal article
000862734 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1571138121_14907
000862734 3367_ $$2BibTeX$$aARTICLE
000862734 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000862734 3367_ $$00$$2EndNote$$aJournal Article
000862734 520__ $$aBackgroundO-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET has a sensitivity of more than 90% to detect gliomas. In the remaining small fraction of gliomas without increased tracer uptake, some tumors even show photopenic defects whose clinical significance is unclear.MethodsGlioma patients with a negative FET PET scan prior to neuropathological confirmation were identified retrospectively. Gliomas were rated visually as (i) having indifferent FET uptake or (ii) photopenic, if FET uptake was below background activity. FET uptake in the area of signal hyperintensity on the T2/fluid attenuated inversion recovery–weighted MRI was evaluated by mean standardized uptake value (SUV) and mean tumor-to-brain ratio (TBR). The progression-free survival (PFS) of photopenic gliomas was compared with that of gliomas with indifferent FET uptake.ResultsOf 100 FET-negative gliomas, 40 cases with photopenic defects were identified. Fifteen of these 40 cases (38%) had World Health Organization (WHO) grades III and IV gliomas. FET uptake in photopenic gliomas was significantly decreased compared with both the healthy-appearing brain tissue (SUV, 0.89 ± 0.26 vs 1.08 ± 0.23; P < 0.001) and gliomas with indifferent FET uptake (TBR, 0.82 ± 0.09 vs 0.96 ± 0.13; P < 0.001). Irrespective of the applied treatment, isocitrate dehydrogenase (IDH)–mutated WHO grade II diffuse astrocytoma patients with indifferent FET uptake (n = 25) had a significantly longer PFS than patients with IDH-mutated diffuse astrocytomas (WHO grade II) with photopenic defects (n = 11) (51 vs 24 mo; P = 0.027). The multivariate survival analysis indicated that photopenic defects predict an unfavorable PFS (P = 0.009).ConclusionPhotopenic gliomas in negative FET PET scans should be managed more actively, as they seem to have a higher risk of harboring a higher-grade glioma and an unfavorable outcome.
000862734 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000862734 588__ $$aDataset connected to CrossRef
000862734 7001_ $$0P:(DE-HGF)0$$aUnterrainer, Marcus$$b1
000862734 7001_ $$0P:(DE-Juel1)143958$$aJudov, Natalie$$b2$$ufzj
000862734 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b3$$ufzj
000862734 7001_ $$0P:(DE-HGF)0$$aRapp, Marion$$b4
000862734 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b5$$ufzj
000862734 7001_ $$0P:(DE-HGF)0$$aVettermann, Franziska$$b6
000862734 7001_ $$0P:(DE-Juel1)156211$$aDunkl, Veronika$$b7
000862734 7001_ $$0P:(DE-HGF)0$$aSuchorska, Bogdana$$b8
000862734 7001_ $$0P:(DE-HGF)0$$aTonn, Jörg C$$b9
000862734 7001_ $$0P:(DE-HGF)0$$aKreth, Friedrich-Wilhem$$b10
000862734 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b11$$ufzj
000862734 7001_ $$0P:(DE-HGF)0$$aBartenstein, Peter$$b12
000862734 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b13$$ufzj
000862734 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie L$$b14
000862734 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noz083$$gp. noz083$$n10$$p1331-1338$$tNeuro-Oncology$$v21$$x1523-5866$$y2019
000862734 8564_ $$uhttps://juser.fz-juelich.de/record/862734/files/noz083.pdf$$yRestricted
000862734 8564_ $$uhttps://juser.fz-juelich.de/record/862734/files/reprint_12816128.pdf
000862734 8564_ $$uhttps://juser.fz-juelich.de/record/862734/files/reprint_12816128.pdf?subformat=pdfa$$xpdfa
000862734 8564_ $$uhttps://juser.fz-juelich.de/record/862734/files/noz083.pdf?subformat=pdfa$$xpdfa$$yRestricted
000862734 8767_ $$8E12816128$$92019-06-20$$d2019-07-30$$eColour charges$$jZahlung erfolgt$$zRechnung mehrmals neu angefordert TAX
000862734 909CO $$ooai:juser.fz-juelich.de:862734$$pOpenAPC$$pVDB$$popenCost
000862734 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b0$$kFZJ
000862734 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143958$$aForschungszentrum Jülich$$b2$$kFZJ
000862734 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b3$$kFZJ
000862734 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b5$$kFZJ
000862734 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b11$$kFZJ
000862734 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b13$$kFZJ
000862734 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000862734 9141_ $$y2019
000862734 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000862734 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2017
000862734 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000862734 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000862734 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000862734 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000862734 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000862734 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000862734 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000862734 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000862734 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2017
000862734 920__ $$lyes
000862734 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000862734 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000862734 980__ $$ajournal
000862734 980__ $$aVDB
000862734 980__ $$aI:(DE-Juel1)INM-3-20090406
000862734 980__ $$aI:(DE-Juel1)INM-4-20090406
000862734 980__ $$aAPC
000862734 980__ $$aUNRESTRICTED
000862734 9801_ $$aAPC